Amanda Belsterling, MD
Neurology · Auburn, ALNPI 1558651570
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,241, 6.2 times the $201 reported in 2019.
Across 282 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$890
- Acadia Pharmaceuticals Inc$439
- Supernus Pharmaceuticals, Inc.$361
- Biogen$326
- Pfizer$324
- Amgen$279
- plus $2K from 31 others
What the payments were for
- Speaking & faculty fees$491%
- Food & beverage$4,55799%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $890 |
| Acadia Pharmaceuticals Inc | 20 | $439 |
| Supernus Pharmaceuticals, Inc. | 30 | $361 |
| Biogen | 25 | $326 |
| Pfizer | 31 | $324 |
| Amgen(2 entities) | 12 | $279 |
| Teva Pharmaceuticals USA, Inc. | 20 | $266 |
| UCB, Inc. | 9 | $210 |
| Catalyst Pharmaceuticals, Inc. | 7 | $159 |
| Genentech USA, Inc. | 6 | $127 |
| Eisai Inc. | 5 | $119 |
| Lilly USA, LLC | 6 | $100 |
| Neurocrine Biosciences, Inc. | 4 | $87 |
| Novartis | 4 | $85 |
| Jazz Pharmaceuticals Inc. | 3 | $75 |
| Biohaven Pharmaceuticals, Inc. | 4 | $71 |
| Johnson & Johnson | 4 | $68 |
| Acorda Therapeutics, Inc | 3 | $67 |
| Bristol Myers Squibb | 4 | $63 |
| AstraZeneca | 2 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| Scilex Pharmaceuticals Inc. | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $50 |
| SK Life Science, Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Greenwich Biosciences, Inc. | 1 | $23 |
| Upsher-smith Laboratories LLC | 1 | $23 |
| Tanabe Pharma America, Inc. | 1 | $21 |
| Neurelis, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Argenx US, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Avion Pharmaceuticals | 1 | $17 |
| TG Therapeutics, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$106
How this compares
$4,609 in reported general payments places this provider in the 55th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 22 | $225,165 |
| IngrezzaValbenazine Tosylate | 18 | $166,951 |
| VumerityDiroximel Fumarate | 18 | $147,965 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 12 | $91,776 |
| BotoxOnabotulinumtoxina | 36 | $54,427 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $52,627 |
| Dimethyl Fumarate | 22 | $48,773 |
| Emgality PenGalcanezumab-Gnlm | 31 | $29,329 |
| Lacosamide | 73 | $26,838 |
| Dalfampridine ErDalfampridine | 49 | $20,611 |
| Oxtellar XrOxcarbazepine | 12 | $16,092 |
| UbrelvyUbrogepant | 11 | $12,702 |
| NamzaricMemantine Hcl/Donepezil Hcl | 11 | $8,382 |
| Pyridostigmine Bromide | 58 | $7,625 |
| Gabapentin | 264 | $6,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $87 | $166,95118 claims |
| BiogenVumerity | $326 | $147,96518 claims |
| PfizerOctagam | $324 | $91,77612 claims |
| AbbVieBotox, Ubrelvy, Namzaric | $890 | $75,51158 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $361 | $16,09212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 255 neurology providers in Alabama.
Other neurology in Auburn
- Diane CounceBirmingham$895K
- Daniel DeesMobile$799K
- Christopher LagankeCullman$711K
- Hayden LongMobile$386K
- Harry McDarisHuntsville$307K
- Belinda Savage-EdwardsHuntsville$296K
- Emily RiserBirmingham$231K
- Nojan ValadiOpelika$219K
- Charles MarkleMobile$212K
- Timothy PrestleyTuscaloosa$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.